Lihua Bao1, Patrick N Cunningham1, Richard J Quigg2. 1. Section of Nephrology, Department of Medicine, University of Chicago, Chicago, Ill., USA. 2. Division of Nephrology, University at Buffalo School of Medicine, Buffalo, N.Y., USA.
Abstract
BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disorder caused by loss of tolerance to self-antigens, the production of autoantibodies and deposition of complement-fixing immune complexes (ICs) in injured tissues. SLE is characterized by a wide range of clinical manifestations and targeted organs, with lupus nephritis being one of the most serious complications. The complement system consists of three pathways and is tightly controlled by a set of regulatory proteins to prevent injudicious complement activation on host tissue. The involvement of the complement system in the pathogenesis of SLE is well accepted; yet, its exact role is still not clear. SUMMARY: Complement plays dual roles in the pathogenesis of SLE. On the one hand, the complement system appears to have protective features in that hereditary homozygous deficiencies of classical pathway components, such as C1q and C4, are associated with an increased risk for SLE. On the other hand, IC-mediated activation of complement in affected tissues is clearly evident in both experimental and human SLE along with pathological features that are logical consequences of complement activation. Studies in genetically altered mice have shown that lack of complement inhibitors, such as complement factor H (CFH) or decay-accelerating factor (DAF) accelerates the development of experimental lupus nephritis, while treatment with recombinant protein inhibitors, such as Crry-Ig, CR2-Crry, CR2-DAF and CR2-CFH, ameliorates the disease development. Complement-targeted drugs, including soluble complement receptor 1 (TP10), C1 esterase inhibitor and a monoclonal anti-C5 antibody (eculizumab), have been shown to inhibit complement safely, and are now being investigated in a variety of clinical conditions. KEY MESSAGES: SLE is an autoimmune disorder which targets multiple systems. Complement is centrally involved and plays dual roles in the pathogenesis of SLE. Studies from experimental lupus models and clinical trials support the use of complement-targeted therapy in the treatment of SLE.
BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disorder caused by loss of tolerance to self-antigens, the production of autoantibodies and deposition of complement-fixing immune complexes (ICs) in injured tissues. SLE is characterized by a wide range of clinical manifestations and targeted organs, with lupus nephritis being one of the most serious complications. The complement system consists of three pathways and is tightly controlled by a set of regulatory proteins to prevent injudicious complement activation on host tissue. The involvement of the complement system in the pathogenesis of SLE is well accepted; yet, its exact role is still not clear. SUMMARY: Complement plays dual roles in the pathogenesis of SLE. On the one hand, the complement system appears to have protective features in that hereditary homozygous deficiencies of classical pathway components, such as C1q and C4, are associated with an increased risk for SLE. On the other hand, IC-mediated activation of complement in affected tissues is clearly evident in both experimental and humanSLE along with pathological features that are logical consequences of complement activation. Studies in genetically altered mice have shown that lack of complement inhibitors, such as complement factor H (CFH) or decay-accelerating factor (DAF) accelerates the development of experimental lupus nephritis, while treatment with recombinant protein inhibitors, such as Crry-Ig, CR2-Crry, CR2-DAF and CR2-CFH, ameliorates the disease development. Complement-targeted drugs, including soluble complement receptor 1 (TP10), C1 esterase inhibitor and a monoclonal anti-C5 antibody (eculizumab), have been shown to inhibit complement safely, and are now being investigated in a variety of clinical conditions. KEY MESSAGES: SLE is an autoimmune disorder which targets multiple systems. Complement is centrally involved and plays dual roles in the pathogenesis of SLE. Studies from experimental lupus models and clinical trials support the use of complement-targeted therapy in the treatment of SLE.
Authors: Marie-Claude Mathieu; Nicole Sawyer; Gillian M Greig; Martine Hamel; Stacia Kargman; Yves Ducharme; Cheuk K Lau; Richard W Friesen; Gary P O'Neill; Francois G Gervais; Alex G Therien Journal: Immunol Lett Date: 2005-03-25 Impact factor: 3.685
Authors: Christoffer T Nielsen; Ole Østergaard; Line Stener; Line V Iversen; Lennart Truedsson; Birgitta Gullstrand; Søren Jacobsen; Niels H H Heegaard Journal: Arthritis Rheum Date: 2012-01-11
Authors: Andreas Jönsen; Sara C Nilsson; Emma Ahlqvist; Elisabet Svenungsson; Iva Gunnarsson; Karin G Eriksson; Anders Bengtsson; Agneta Zickert; Maija-Leena Eloranta; Lennart Truedsson; Lars Rönnblom; Gunnel Nordmark; Gunnar Sturfelt; Anna M Blom Journal: Arthritis Res Ther Date: 2011-12-15 Impact factor: 5.156
Authors: Harold L Lazar; Paula M Bokesch; Frederick van Lenta; Carmel Fitzgerald; Constance Emmett; Henry C Marsh; Una Ryan Journal: Circulation Date: 2004-09-14 Impact factor: 29.690
Authors: Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen Journal: Blood Date: 2007-11-30 Impact factor: 22.113
Authors: Ana Paula Alegretti; Laiana Schneider; Amanda Kirchner Piccoli; Odirlei Andre Monticielo; Priscila Schmidt Lora; João Carlos Tavares Brenol; Ricardo Machado Xavier Journal: Clin Dev Immunol Date: 2012-06-12
Authors: Jenny U Johansson; William D Brubaker; Harold Javitz; Andrew W Bergen; Denise Nishita; Abhishek Trigunaite; Andrés Crane; Justine Ceballos; Diego Mastroeni; Andrea J Tenner; Marwan Sabbagh; Joseph Rogers Journal: Alzheimers Dement Date: 2018-05-21 Impact factor: 21.566
Authors: Myriam Martin; Karolina I Smoląg; Albin Björk; Birgitta Gullstrand; Marcin Okrój; Jonatan Leffler; Andreas Jönsen; Anders A Bengtsson; Anna M Blom Journal: Arthritis Res Ther Date: 2017-12-06 Impact factor: 5.156
Authors: Evan Mulvihill; Stacy Ardoin; Susan D Thompson; Bi Zhou; Gakit Richard Yu; Emily King; Nora Singer; D M Levy; Hermine Brunner; Yee Ling Wu; Haikady N Nagaraja; Laura Eve Schanberg; Chack-Yung Yu Journal: Lupus Sci Med Date: 2019-07-31
Authors: Anne Troldborg; Lisbeth Jensen; Bent Deleuran; Kristian Stengaard-Pedersen; Steffen Thiel; Jens Christian Jensenius Journal: Front Immunol Date: 2018-03-26 Impact factor: 7.561